We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-1.29%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$2.33B
AUM Growth
+$549M
(+31%)
Cap. Flow
+$131M
Cap. Flow
% of AUM
5.6%
Top 10 Holdings %
Top 10 Hldgs %
56.72%
Holding
316
New
83
Increased
72
Reduced
72
Closed
65
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Weyerhaeuser
WY
|
+$59M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$33.1M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$9.18M |
| 4 |
AGN
Allergan plc
AGN
|
+$6.91M |
| 5 |
CNSY
Cerenome
CNSY
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$12.1M |
| 2 |
BPTH
Bio-Path Holdings Inc
BPTH
|
+$8.78M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$7.12M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$6.23M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$4.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 86.57% |
| 2 | Healthcare | 9.72% |
| 3 | Real Estate | 2.82% |
| 4 | Energy | 0.36% |
| 5 | Consumer Discretionary | 0.23% |
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q2 2014 Portfolio in Review
As of Q2 2014, Sabby Management held 316 positions worth $2.33B, up 31% from $1.78B the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Sabby Management deployed $131M of net new capital in Q2 2014, opening 83 new positions and adding to 72 existing holdings. Its largest new stake was Weyerhaeuser: 1,950,977 shares worth $64.6M.
By sector, the portfolio is most concentrated in Miscellaneous at 87% of assets, down from 89% a quarter earlier, followed by Healthcare and Real Estate.
On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $7.12M trimmed.
- Sabby Management's largest Q2 2014 buy was Weyerhaeuser: 1,950,977 shares worth $64.6M.
- Sabby Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $33.1M increase.
- Sabby Management's biggest Q2 2014 reduction was Sarepta Therapeutics, cutting an estimated $7.12M.
- Sabby Management fully exited Gilead Sciences in Q2 2014, selling an estimated $12.1M.
- Sabby Management's ten largest holdings make up 57% of its $2.33B portfolio in Q2 2014.
- Sabby Management opened 83 new positions and closed 65 in Q2 2014.
- Sabby Management's portfolio value rose 31% quarter-over-quarter to $2.33B.
Based on Sabby Management's 13F filing for Q2 2014, filed 14 Aug 2014.